Downloaded from http://jcp.bmj.com/ on October 18, 2015 - Published by group.bmj.com
JCP Online First, published on July 8, 2015 as 10.1136/jclinpath-2015-202978 Original article
New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma Fangfang Liu,1 Danhua Shen,1 Xiaoping Kang,2 Chunfang Zhang,3 Qiujing Song1 ▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ jclinpath-2013-202978). 1
Department of Pathology, Peking University People’s Hospital, Beijing, China 2 Department of Statistics Office, Peking University Health Science Center, Beijing, China 3 Department of Clinical Epidemiology, Peking University People’s Hospital, Beijing, China Correspondence to Professor Fangfang Liu, Department of Pathology, Peking University People’s Hospital, Beijing 100044, China; [email protected] Received 1 March 2015 Revised 17 June 2015 Accepted 21 June 2015
ABSTRACT Aim To evaluate protein expression and clinical significance of PLAC1/CP1 antigen in primary gastric adenocarcinoma. Methods Protein expression of PLAC1/CP1 was analysed by tissue chip and immunohistochemistry in surgical specimens obtained from 119 patients with gastric cancer. The data were analysed using SPSS V.16.0 software applying the χ2 test and Kaplan-Meier method. Results The positive expression frequency of PLAC1/ CP1 protein was 61.3% (73/119 patients). The overall survival of patients with PLAC1/CP1 protein-positive expression was significantly lower than that of patients with PLAC1/CP1 protein-negative expression ( p50 ≤50 Tumor differentiation Well-to-moderate Poorly TNM staging Stage I+II Stage III+IV Lymph node metastasis No metastasis Metastasis Tumour location Antrum and pylorus Body Fundus and cardia Size (cm) >3 ≤3 Survival Live Death Survival time (month) PLAC1/CP1 (protein−) PLAC1/CP1 (protein+) Bold type indicates p
JCP Online First, published on July 8, 2015 as 10.1136/jclinpath-2015-202978 Original article
New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma Fangfang Liu,1 Danhua Shen,1 Xiaoping Kang,2 Chunfang Zhang,3 Qiujing Song1 ▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ jclinpath-2013-202978). 1
Department of Pathology, Peking University People’s Hospital, Beijing, China 2 Department of Statistics Office, Peking University Health Science Center, Beijing, China 3 Department of Clinical Epidemiology, Peking University People’s Hospital, Beijing, China Correspondence to Professor Fangfang Liu, Department of Pathology, Peking University People’s Hospital, Beijing 100044, China; [email protected] Received 1 March 2015 Revised 17 June 2015 Accepted 21 June 2015
ABSTRACT Aim To evaluate protein expression and clinical significance of PLAC1/CP1 antigen in primary gastric adenocarcinoma. Methods Protein expression of PLAC1/CP1 was analysed by tissue chip and immunohistochemistry in surgical specimens obtained from 119 patients with gastric cancer. The data were analysed using SPSS V.16.0 software applying the χ2 test and Kaplan-Meier method. Results The positive expression frequency of PLAC1/ CP1 protein was 61.3% (73/119 patients). The overall survival of patients with PLAC1/CP1 protein-positive expression was significantly lower than that of patients with PLAC1/CP1 protein-negative expression ( p50 ≤50 Tumor differentiation Well-to-moderate Poorly TNM staging Stage I+II Stage III+IV Lymph node metastasis No metastasis Metastasis Tumour location Antrum and pylorus Body Fundus and cardia Size (cm) >3 ≤3 Survival Live Death Survival time (month) PLAC1/CP1 (protein−) PLAC1/CP1 (protein+) Bold type indicates p
